Epidermal growth factor receptor is expressed and active in a subset of acute myeloid leukemia

Hasan Mahmud, Steven M. Kornblau, Arja Ter Elst, Frank J.G. Scherpen, Yi Hua Qiu, Kevin R. Coombes, Eveline S.J.M. De Bont

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


The epidermal growth factor receptor (EGFR) inhibitor erlotinib has been shown to induce complete remission of acute myeloid leukemia (AML) in two patients with concurrent lung cancer and raised attention for a role of EGFR in AML whereas a recent phase II clinical study with gefitinib in AML demonstrated a negative result on the outcome. However, from several studies, EGFR expression in AML is poorly defined and the role of EGFR in AML remains unclear. Herein, we report the results of EGFR expression in AML of large cohorts of adult and pediatric AML patients with the data of total protein and phosphorylation levels of EGFR. Our data conclude that there is the expression of EGFR at the protein level in a subset of AML, which was identified to be functionally active in ~15 % of AML patients. This suggests that future studies need to be conducted with a subset of AML patients characterized by high EGFR expression.

Original languageEnglish
Article number64
JournalJournal of Hematology and Oncology
Issue number1
StatePublished - 3 Aug 2016
Externally publishedYes


  • AML
  • EGFR
  • Kinome
  • Leukemia
  • RPPA


Dive into the research topics of 'Epidermal growth factor receptor is expressed and active in a subset of acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this